Managing Adverse Events Associated with 1L Regimens for CLL and SLL

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the evaluation form and your certificate of credit will be generated.

Activity Description:
The success of novel targeted therapies and fixed dosing schedules for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) can be limited by adverse events (AEs). It has been increasingly important that oncology nurse teams have an established protocol for AE management to improve patient outcomes. Join our expert faculty in this 15-minute interactive case-based discussion on best practices to handle common AEs in CLL/SLL patients receiving first-line treatment.

This CE activity is intended for oncology nurses and NPs who provide care for individuals with CLL and SLL.

After completing this CE activity, the participant should be better able to:

  • Select safe and effective fixed-duration combinations to improve patient care and outcomes
  • Identify the most common and serious adverse events (AEs) that emerge during treatment with targeted therapies and combination regimens, including negative outcomes associated with mutations in black patients
  • Plan strategies to mitigate treatment-emergent AEs most troublesome for patients
  • Engage patients of all backgrounds and ethnicities in discussion of the risks of AEs relative to treatment outcomes

Joint Accreditation with Commendation LogoIn support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 0.25 contact hour and 0.25 contact hour in the area of pharmacology.

Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Tajuana Bradley, MSN, APRN-BC has financial interest/relationship or affiliation in the form of:

Speaker’s Bureau: ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Coherus BioSciences, G1 Therapeutics, Puma Biotechnology, SeaGen

 

Amy Goodrich, RN, MSN, CRNP, has financial interest/relationship or affiliation in the form of:


Advisory Board/Consultant for AbbVie, Epizyme, Janssen

 

All of the relevant financial relationships of individuals for this activity have been mitigated.

The planners and content/peer reviewers from Medical Learning Institute, Inc., do not have any relevant financial relationship(s) to disclose with ineligible companies.

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the evaluation form and your certificate of credit will be generated.

For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

If you have questions regarding your certificate, please contact Nicole Dane via email at ndane@mlieducation.org.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters

Support Statement
Supported by educational grants from Genentech, a member of the Roche Group and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.